Quince Therapeutics (NASDAQ:QNCX) Given New $5.00 Price Target at D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX) had its target price hoisted by analysts at D. Boral Capital from $4.00 to $5.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. D. Boral Capital’s target price indicates a potential upside of 29.70% from the stock’s current price.

Several other brokerages have also recently issued reports on QNCX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quince Therapeutics in a report on Monday, December 8th. Zacks Research raised shares of Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.20.

Quince Therapeutics Price Performance

Shares of Quince Therapeutics stock traded down $0.37 during trading on Monday, reaching $3.86. 955,662 shares of the stock traded hands, compared to its average volume of 333,276. Quince Therapeutics has a 52-week low of $0.72 and a 52-week high of $4.55. The business has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $1.84. The company has a market capitalization of $214.65 million, a price-to-earnings ratio of -3.19 and a beta of 1.02.

Quince Therapeutics (NASDAQ:QNCX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). On average, research analysts predict that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Quince Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QNCX. XTX Topco Ltd purchased a new position in Quince Therapeutics during the 2nd quarter valued at about $37,000. Virtu Financial LLC increased its holdings in Quince Therapeutics by 48.4% during the first quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after buying an additional 14,128 shares during the period. GSA Capital Partners LLP raised its stake in Quince Therapeutics by 158.0% in the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after buying an additional 53,417 shares in the last quarter. Bridgeway Capital Management LLC lifted its holdings in Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after buying an additional 22,200 shares during the period. Finally, Rockefeller Capital Management L.P. purchased a new stake in Quince Therapeutics during the second quarter worth $280,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.